Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2003

View Archived Issues

Business highlights at Regeneron

Scancell and Celltech collaborate on antibody therapeutics to Lewis(y/b)

Levitra is effective in men of diverse ethnic origin

New NHE-3 inhibitors and their use covered by Merck KGaA patent

Merck KGaA presents novel PDE7 inhibitors

New PARP inhibitors in early development at Fujisawa

Dual 5-HT/noradrenaline uptake inhibitors and their use described by Lundbeck

MMP inhibitors, their preparation and biological evaluation reported by Sumitomo

Micrologix claims new L-nucleoside derivatives with anti-HBV activity

EP2 receptor agonist CP-533536 offers a therapeutic alternative for bone fractures and defects

E.U. orphan drug status awarded to Fidelin for adrenal insufficiency

Pivotal phase III trial for Cellegesic makes solid progress

CART-2 trial of AGI-1067 completes enrollment

Lapdap approved by U.K. agency for treatment of P. falciparum malaria

EFECT studies new breast cancer population for Faslodex

Quark Biotech and Fujisawa extend stroke collaboration

ACP-103 completes phase I testing

FDA panel recommends Onyx for treatment of arteriovenous malformations

Phase III study for RSD-1235 in atrial fibrillation commences dosing

Combination of NF-kB inhibitors and DNA-damaging agents for improving therapeutic outcome

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...